Summary
This phase 2 trial, published in The Lancet in 2016, evaluated atezolizumab as a first-line immunotherapy option for patients with advanced urothelial carcinoma who were ineligible for cisplatin-based chemotherapy. The study was conducted across multiple centres and assessed clinical efficacy and safety endpoints in this patient population. As suggested by the trial design, the findings contributed to establishing immunotherapy as a viable treatment option for cisplatin-ineligible patients with advanced bladder cancer.
UK applicability
This trial's findings are relevant to UK oncology practice and NHS treatment protocols for advanced urothelial carcinoma, particularly for patients with contraindications to cisplatin. The study informs clinical guidance on immunotherapy options within the UK cancer care pathway.
Key measures
Objective response rate, disease control rate, safety and tolerability outcomes, progression-free survival, overall survival
Outcomes reported
The study evaluated safety, tolerability, and efficacy of atezolizumab (a PD-L1 inhibitor) as first-line treatment in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma. Primary endpoints were response rate and safety profile.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.